AZM-152
Bronchopulmonary Dysplasia (BPD) Prevention
Key Facts
About Azome Therapeutics
Azome Therapeutics is a private, preclinical-stage biotech targeting the NLRP3 inflammasome with a novel, upstream approach via its lead candidate AZM-152. The company is initially pursuing severe inflammatory pulmonary diseases with high unmet need, such as ARDS, BPD, and IPF exacerbations. A key recent milestone is a CRADA with the National Center for Advancing Translational Sciences to advance AZM-152 for BPD prevention. Azome represents a specialized player in the competitive inflammasome space, with a strategy focused on intercepting the pathway before full activation.
View full company profileAbout Azome Therapeutics
Azome Therapeutics is a private, preclinical-stage biotech targeting the NLRP3 inflammasome with a novel, upstream approach via its lead candidate AZM-152. The company is initially pursuing severe inflammatory pulmonary diseases with high unmet need, such as ARDS, BPD, and IPF exacerbations. A key recent milestone is a CRADA with the National Center for Advancing Translational Sciences to advance AZM-152 for BPD prevention. Azome represents a specialized player in the competitive inflammasome space, with a strategy focused on intercepting the pathway before full activation.
View full company profileAbout Azome Therapeutics
Azome Therapeutics is a private, preclinical-stage biotech targeting the NLRP3 inflammasome with a novel, upstream approach via its lead candidate AZM-152. The company is initially pursuing severe inflammatory pulmonary diseases with high unmet need, such as ARDS, BPD, and IPF exacerbations. A key recent milestone is a CRADA with the National Center for Advancing Translational Sciences to advance AZM-152 for BPD prevention. Azome represents a specialized player in the competitive inflammasome space, with a strategy focused on intercepting the pathway before full activation.
View full company profileAbout Azome Therapeutics
Azome Therapeutics is a private, preclinical-stage biotech targeting the NLRP3 inflammasome with a novel, upstream approach via its lead candidate AZM-152. The company is initially pursuing severe inflammatory pulmonary diseases with high unmet need, such as ARDS, BPD, and IPF exacerbations. A key recent milestone is a CRADA with the National Center for Advancing Translational Sciences to advance AZM-152 for BPD prevention. Azome represents a specialized player in the competitive inflammasome space, with a strategy focused on intercepting the pathway before full activation.
View full company profile